Type 1 Diabetes

The designation means that pharmacists can switch patients to the less-expensive version of insulin without seeking approval from the clinician.

Aleksandar Kostic, PhD, an assistant professor of microbiology at Harvard Medical School, explains how a microbially targeted vaccine may prevent type 1 diabetes (T1D).

In a new review, researchers assessed the negative impacts of glycemic variability on cognitive function and brain structure among youth with type 1 diabetes.

Ezio Bonifacio, PhD, explains factors associated with childhood type 1 diabetes incidence and why more research is needed among minority populations.

In Germany, rates of diabetic ketoacidosis (DKA) seen at time of type 1 diabetes (T1D) diagnosis were stable throughout the past 2 decades.

Ann Goebel-Fabbri, PhD, a clinical psychologist in Boston, Massachusettes, discusses how limited research on patients with type 1 diabetes (T1D) and eating disorders hinders progress on developing effective interventions.

Mary Pat Gallagher, MD, of NYU Langone Health, discusses research needed to better understand how COVID-19 impacts individuals with diabetes.

Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA), outlines why updates were made to the ADA’s Living Standards of Care.

Camillo Ricordi, MD, FNAI, describes the process of islet transplantation and how it can benefit individuals with type 1 diabetes.

Leslie Eiland, MD, discusses the benefits of remote monitoring among patients with type 1 diabetes (T1D) living in rural America.

Aleksandar Kostic, PhD, an assistant professor of microbiology at Harvard Medical School, describes the research linking gut microbiota and incidence of type 1 diabetes.

Ezio Bonifacio, PhD, discusses the optimal time to begin monitoring for type 1 diabetes (T1D) in children genetically at risk for the disease.

Ann Goebel-Fabbri, PhD, a clinical psychologist in Boston, Massachusettes, outlines trends in eating disorders among patients with type 1 diabetes.

Mary Pat Gallagher, MD, of NYU Langone Health, explains her research documenting new onset diabetes and diabetic ketoacidosis (DKA) throughout the COVID-19 pandemic.

The American Diabetes Association's chief scientific and medical officer said the results are important to families at risk of type 1 diabetes.

New CMS changes aim to broaden coverage of continuous glucose monitoring (CGM) devices.

Study results indicate COVID-19 transmission mitigation efforts may have led to delayed diagnoses of type 1 diabetes (T1D) in Finnish children, resulting in more cases of diabetic ketoacidosis at presentation.

National Institutes of Health–sponsored research examines the underlying cause of COVID-19–induced diabetes.

Results of a systematic review underscore implications of increased rates of metabolic syndrome among youth with type 1 diabetes.

Results of a nationwide study show earlier onset of type 1 diabetes (T1D) is associated with worse glycemic outcomes and presence of albuminuria.

Results of a study conducted in California suggest some adolescents with type 1 diabetes (T1D) improved their glycemic control during the COVID-19 lockdown.

Data from a longitudinal study reveal poor glycemic control and blood pressure management may contribute to cognitive decline in older patients with type 1 diabetes.

FDA panel members acknowledged the challenges and significant unmet need that patients with T1D face, along with the small size of the pivotal study.

A recent analysis of The Environmental Determinants of Diabetes in the Young study found maternal diet has no impact on type 1 diabetes and islet autoimmunity (IA) risk.

Results of a qualitative study outline widely held cost considerations regarding diabetes technology in the type 1 diabetes (T1D) community.